Made Scientific and Streamline Bio Launch AI Robotics for Cell Therapies

Made Scientific, a prominent contract development and manufacturing organization (CDMO) for cell therapies, and Streamline Bio, an innovative robotics company, have announced a collaboration aimed at enhancing the manufacturing process for cell and gene therapies. On October 6, 2025, the companies revealed the successful validation of Streamline Bio’s AI-driven robotics platform in a live production environment at Made Scientific’s facility in Princeton, NJ.

The collaboration marks a significant step toward integrating this advanced technology into good manufacturing practices (GMP). Following the validation phase, both companies are gearing up to launch early-adopter programs and further develop a fully robotic manufacturing solution intended for cell therapy innovators.

Streamline Bio’s platform tackles critical challenges within the cell and gene therapy (CGT) sector, particularly addressing manufacturing complexities, high costs, and quality variability common in current therapies. Unlike traditional, rigid robotic solutions that require extensive infrastructure, Streamline Bio’s system is designed with flexibility in mind. It can easily adapt to various equipment and protocols, thus minimizing the need for significant process alterations or custom setups.

By automating labor-intensive processes, the platform not only reduces the burden on operators but also lowers the risk of human error. This technological advancement allows skilled personnel to concentrate on higher-value activities while ensuring complete data traceability through a digital-first approach.

As part of their ongoing collaboration, Made Scientific and Streamline Bio are preparing the platform for GMP deployment, utilizing systems such as Miltenyi CliniMACS Prodigy®, G-Rex®, and Fresenius-Kabi LOVO®. The integration of Streamline Bio’s fully robotic platform into Made Scientific’s GMP cleanrooms aims to demonstrate efficient orchestration of complex workflows, paving the way for commercial-scale applications.

Rodney Rietze, Ph.D., President and CEO of Streamline Bio, commented on the significance of this technology, stating, “Today’s CGT processes are incredibly nuanced and complex. Streamline Bio’s robotic platform allows cell and gene therapy developers and manufacturers to respond with automation that’s not only smart and scalable, but inherently adaptive.”

Similarly, Syed T. Husain, Chairman and CEO of Made Scientific, expressed enthusiasm about the partnership, noting, “Streamline Bio is redefining manufacturing by offering an innovative, flexible, and scalable platform aimed at making transformative therapies more accessible to patients.”

Both organizations view this collaboration as a way to ultimately impact the cost, process, product reproducibility, and time-to-clinic for emerging therapies. Future studies are expected to further validate the platform’s capabilities, including automated analytical and quality control testing workflows.

As cell and gene therapy markets continue to expand, the integration of advanced robotics and AI-driven solutions presents a promising avenue for enhancing manufacturing processes, ultimately improving patient access to groundbreaking therapies.